Do Regulatory And Drug-Pricing Worries Mark The End Of Biotech’s Heyday?

The prospect of tighter regulation of the sector (particularly when it comes to mergers and drug approvals) and drug-pricing reform, as well as rising interest rates, have created a “perfect storm” bearing down on biotech stocks. As a result, after seeing massive gains in 2020, biotech stocks have pulled back. Do biotech investors have reason to worry, or is biotech’s heyday not over yet? CLICK HERE.